Intestinal ischemia–reperfusion (IR) is a frequently occurring phenomenon during
abdominal and thoracic vascular surgery, small bowel transplantation, hemorrhagic
shock, and surgery using cardiopulmonary bypass, carrying high morbidity and
mortality. Ambroxol hydrochloride is an active N-desmethyl metabolite of
bromhexine hydrochloride. Ambroxol is indicated as ‘secretolytic therapy in
bronchopulmonary diseases associated with abnormal mucus secretion and
impaired mucus transport’.
Aim
The present study was designed to evaluate the effect of ambroxol on
experimentally induced acute organ oxidative stress in the form of remote organ
injury including kidney and heart after intestinal IR.
Materials and methods
Thirty animals were classified into five groups. First group: normal control group,
second group: nontreated intestinal IR group (intestinal IR was induced by
mesenteric artery ligation), third group: ambroxol pretreated intestinal IR group
(35 mg/kg), fourth group: ambroxol pretreated intestinal IR group (70 mg/kg), fifth
group: ambroxol pretreated intestinal IR group (140 mg/kg).
Results
Ambroxol significantly reduced the malondialdehyde level in the heart and the
kidney when compared with intestinal IR with no medication group. It also improved
cardiac troponin and, kidney functions (urea and creatinine) and histopathological
affection when compared with intestinal IR with no medication group. Conclusively,
in this study ambroxol could have a protective effect against intestinal IR through its
antioxidative and anti-inflammatory effect.
|
